Trial on Secukinumab With or Without GLP-1 RA Co-therapy Registered

A clinical trial listing dated October 20, 2026 describes a new real-world study involving secukinumab and GLP-1 receptor agonist co-therapy. The trial, registered as NCT07881783, is titled "A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy." Dulaglutide is approved and falls within the GLP-1 RA class referenced in this study's scope. The trial's status is listed as not yet recruiting, and no phase is specified in the registration. The study is designed to look at treatment retention and adherence to secukinumab among plaque psoriasis patients, comparing those who receive GLP-1 RA co-therapy with those who do not. No outcomes, results, or efficacy data have been reported as of this listing. Further details on enrollment criteria, timelines, and design have not been disclosed beyond what is stated in the registration. As the study has not yet begun recruiting, no participant data or interim findings are available at this time. Readers interested in background on dulaglutide can consult the compound overview for additional context.